
Rhovica Neuroimaging partners with M2care to advance neurosurgery
9 December 2024

Rhovica Neuroimaging AG, an innovative bernse medtech start-up, has announced a strategic partnership with M2care, a European venture studio specializing in health technologies. This collaboration aims to accelerate the development and commercialization of Rhovica’s cutting-edge solutions in neurocritical care.
Founded in 2023 by neurosurgeons Martin Hlavica and Thomas Rhomberg, Rhovica Neuroimaging focuses on improving treatment for patients with severe cranial trauma and intracranial hemorrhages that result in increased brain pressure. The start-up’s flagship innovation, the SoNav™ system, integrates advanced sensors to provide real-time visualization for the guided and secure insertion of external ventricular drains (EVDs). This technology eliminates the frequent trade-off between speed and precision in emergency and intensive care settings, improving outcomes for critically ill patients.
The SoNav™ system also monitors brain ventricles in real-time, reducing the need for costly and potentially harmful CT scans. By streamlining procedures and enhancing diagnostic capabilities, the technology shortens patient treatment times, helping preserve neurological functions and save lives.
Recognition and market potential
Through its partnership with M2care, Rhovica Neuroimaging will benefit from financial support and operational expertise to bring its life-saving solutions to market. M2care, established by Mérieux Développement and CEA Investissement, specializes in advancing early-stage health tech innovations by connecting academic research, investors, and industry stakeholders.
“M2care’s extensive experience in launching and scaling medtech ventures perfectly complements Rhovica’s innovative approach,” said M2care’s Managing Partner, Carsten Laue. “The SoNav™ system’s intuitive design addresses critical challenges in neurocritical care and promises to elevate patient outcomes worldwide.”
Rhovica Neuroimaging’s rapid rise in the medtech sector has been marked by several accolades, including winning all three stages of the Venture Kick program and being a finalist in the Swiss Technology Award 2024. The global neurocritical care market, valued in the billions, is poised for significant growth, with projected annual increases of up to 14.2%. This makes Rhovica’s technology uniquely positioned to address expanding market demands.